No abstract

Malignant pancreatic tumours induced in athymic mice are a good model for peptide receptor targeted radiotherapy. The objective of this research was to determine biokinetic parameters in mice, in order to estimate the induced pancreatic tumour absorbed doses and to evaluate an 'in house' 177 Lu-DOTA-TATE radiopharmaceutical as part of preclinical studies for targeted therapy in humans. AR42J murine pancreas cancer cells expressing somatostatin receptors, were implanted in athymic mice (n = 22) to obtain biokinetic and dosimetric data of 177 Lu-DOTA-TATE. The mean tumour uptake 2 h post injection was 14.76 ± 1.9% I.A./g; kidney and pancreas uptake, at the same time, were 7.27 ± 1.1% I.A./g (1.71 ± 0.90%/organ) and 4.20 ± 0.98%I.A./g (0.42 ± 0.03%/organ), respectively. The mean absorbed dose to tumour, kidney and pancreas was 0.58 ± 0.02 Gy/MBq; 0.23 ± 0.01 Gy/MBq and 0.14 ± 0.01 Gy/MBq, respectively. These studies justify further dosimetric estimations to ensure that 177 Lu-DOTA-TATE will act as expected in humans.

No abstract

No abstract